Literature DB >> 3115354

Use of a lipid containing medium chain triglycerides in patients receiving TPN: a randomized prospective trial.

P J Clarke1, M J Ball, L J Hands, A R Dennison, A Tunbridge, K White, M G Kettlewell.   

Abstract

Lipid emulsions which contain long chain triglycerides (LCTs) provide a valuable energy source for patients requiring total parenteral nutrition (TPN). We have investigated the use of a new lipid emulsion containing both long and medium chain triglycerides (MCTs) in a randomized prospective trial. Sixty patients received TPN including 500 ml of either 20 per cent Lipofundin S (LCT) or Lipofundin 10 per cent MCT/10 per cent LCT for at least 6 days. Patients with renal or hepatic impairment, or major trauma, were excluded from the study. The MCT/LCT emulsion was found to be as safe and as effective a source of calories as LCT but the differences in metabolic parameters did not differ significantly between the two groups of patients. A lipid emulsion containing MCTs may have important advantages for seriously ill patients, but appears to have no obvious advantages for the majority of patients receiving TPN who are not severely stressed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115354     DOI: 10.1002/bjs.1800740818

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Comparison of medium and long chain triglyceride metabolism in intensive care patients on parenteral nutrition.

Authors:  M J Ball; K White
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

2.  Constant infusion rates of lipid emulsions to stabilize plasma triglyceride concentrations: medium-chain triglyceride/long-chain triglyceride emulsions (MCT/LCT) versus LCT.

Authors:  K Iriyama; C Miki; T Inoue; N Kawarabayashi; H Urata; C Shigemori
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

3.  Parenteral nutrition in the critically ill: use of a medium chain triglyceride emulsion.

Authors:  M J Ball
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.